Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
71 hedge funds and large institutions have $403M invested in Repare Therapeutics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 8 closing their positions.
811% more call options, than puts
Call options by funds: $2.78M | Put options by funds: $305K
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more funds holding
Funds holding: 62 → 71 (+9)
1.48% more ownership
Funds ownership: 77.88% → 79.36% (+1.5%)
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
13% less capital invested
Capital invested by funds: $464M → $403M (-$61M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$28.7M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.25M |
| 3 |
Renaissance Technologies
New York
|
+$1.09M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$967K |
| 5 |
D.E. Shaw & Co
New York
|
+$874K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.39M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.8M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$1.74M |
| 5 |
Millennium Management
New York
|
-$1.6M |
RPTX Hedge Fund Activity: Q2 2022 in Review
71 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q2 2022, worth a combined $403M — down 13% from $464M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RPTX positions and 8 closed out — a net gain of 10 holders — while 19 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, adding an estimated $28.7M. The largest seller was Fidelity Investments, cutting an estimated $18.4M.
- 71 institutional investors held Repare Therapeutics (RPTX) as of Q2 2022, up from 62 in Q1 2022.
- Funds reported $403M of Repare Therapeutics stock for Q2 2022, down 13% quarter-over-quarter.
- 18 funds opened new Repare Therapeutics positions in Q2 2022 and 8 closed out, a net change of +10 holders.
- The largest Repare Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $28.7M added.
- The largest Repare Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $18.4M sold.
Based on aggregated 13F filings for Q2 2022.